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Abstract
Some cancers like melanoma and pancreatic and ovarian cancers, for example, commonly display resistance to
chemotherapy, and this is the major obstacle to a better prognosis of patients. Frequently, literature presents
studies in monolayer cell cultures, 3D cell cultures or in vivo studies, but rarely the same work compares results of
drug resistance in different models. Several of these works are presented in this review and show that usually cells
in 3D culture are more resistant to drugs than monolayer cultured cells due to different mechanisms. Searching for
new strategies to sensitize different tumors to chemotherapy, many methods have been studied to understand the
mechanisms whereby cancer cells acquire drug resistance. These methods have been strongly advanced along the
years and therapies using different drugs have been increasingly proposed to induce cell death in resistant cells of
different cancers. Recently, cancer stem cells (CSCs) have been extensively studied because they would be the only
cells capable of sustaining tumorigenesis. It is believed that the resistance of CSCs to currently used
chemotherapeutics is a major contributing factor in cancer recurrence and later metastasis development. This
review aims to appraise the experimental progress in the study of acquired drug resistance of cancer cells in
different models as well as to understand the role of CSCs as the major contributing factor in cancer recurrence
and metastasis development, describing how CSCs can be identified and isolated.
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Introduction
The use of chemical agents to treat patients with cancer
began with two studies in the 1940s. The synthesis and
application of nitrogen mustard, a derivate compound
from the chemical warfare agent mustard gas which, in
addition to other damages, causes injury to blood cells
and bone marrow degeneration. At the end of the same
decade, observation of the relationship between folic
acid and leukocyte proliferation and synthesis of com-
pounds with antagonistic action to folic acid promoted a
breakthrough in cancer treatment.
In 1942, Alfred Gilman and Louis Goodman treated
a patient with advanced lymphosarcoma, which no lon-
ger responded to radiotherapy or surgery, with nitrogen
mustard. Halfway treatment they could perceive a symp-
tomatic improvement and, at the end of the treatment
period, biopsy revealed no tumor. However, the tumor
reappeared weeks later and the treatment did not cause
the same effect, with the patient’s death weeks later [1].
In another clinical research, Sidney Farber introduced
the administration of folic acid antagonists in patients
with acute leukemia. The results showed that some com-
pounds have the effect of temporarily inhibiting cell pro-
liferation [2].
The results obtained in these two studies were similar
in some aspects, such as the chemical agents being able
to kill cancer cells, causing side effects and reappearance
of tumors exhibiting resistance to the initial treatment.
Subsequently to these events, other research groups
sought to find substances that combined a more effect-
ive action on cancer cells and fewer side effects, as well
as new strategies for drug administration [3-6].
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Thus, drug resistance of cancer cells has been the sub-
ject of intense study. One of the first studies specifically
investigating the resistance to folic acid antagonists was
performed by Law [7]. Based on a study of bacterial re-
sistance to a virus [8], the study of Law was conducted
with the goal to find out the source of resistance of
leukemic cells to folic acid antagonists, coming to the
hypothesis that resistance seemed to arise from random
mutations and selection.
The resistance of tumor cells to cytotoxic drugs is the
major cause of failure of chemotherapy. This resistance,
intrinsic or acquired, is a reflex of the result of numer-
ous genetic and epigenetic alterations in cancer cells
[9-11].
Anticancer drugs have targeted mainly the DNA, acti-
vating or silencing gene expression, and to do so drugs
must penetrate an important cellular barrier, the plasma
membrane. This should work as a line of defense and
physical resistance to many classes of drugs [12,13]. Spe-
cific carriers actively transport some drugs through the
membrane, and the resistance to them can be generated
by reducing the drug carrier affinity or by decreasing the
speed of transport. However, the efflux mechanism is
assumed as the main responsible for the multiple drug
resistance phenotypes.
This type of resistance involves the participation of the
mechanisms of multidrug resistance (MDR), which in-
clude P-glycoprotein (P-gp), belonging to a family of
ATP-dependent transporters. The intrinsic resistance is
characterized by lack of sensitiveness to drug since the
beginning of treatment, which is directly involved in the
drug efflux [14].
Acquired resistance can develop by continuous expos-
ure to drugs, which can trigger different cellular respon-
ses, such as blockage of apoptotic pathways, increased
ability to repair DNA, changes in the control points of
the cell cycle or induction of specific genes.
In the 40’s, nitrogen mustard gas was used as a cy-
totoxic agent. Twenty years later, anticancer drugs de-
rived from natural products (e.g. vinca alkaloids) have
emerged, and these drugs were more harmful against
tumor cells. Nevertheless, until the present days, the
search for effective cancer therapies persists.
Nowell [15] proposed that the tumor develops from a
single cell clone, which acquires selective advantage over
the normal cell that gave rise to it. This hypothesis was
supported by some evidence in common: biochemical
or cytogenetic. Actually, in many primary tumors, cells
exhibit the same abnormal karyotype. Nowell’s pro-
posal gave rise to what is known today as the clonal
evolution model of a tumor cell population, in which
natural selection in tumors leads to evolutionary chan-
ges and possibly drug resistance, ensuring the survival
of cancer.
Another possibility for the development and mainten-
ance of cancer arose when Lapidot et al. [16] and later
Bonnet and Dick [17] found a subpopulation of cells in
human chronic myeloid leukemia, which was capable of
developing the disease in Severe Combined Immunodefi-
ciency or Non-Obese Diabetic/Severe Combined Im-
munodeficiency mice (SCID or NOD/SCID). These cells
showed a phenotype to surface receptors (CD34+/CD38−)
similar to hematopoietic progenitor cells and the same
ability to self-renewal and differentiation, so they were
termed as cancer stem cells (CSCs). It was also confirmed
the presence of CSCs in several solid tumors (reviewed by
Visvader and Lindeman [18]).
The purpose of this review is to report the main mo-
lecular mechanisms that lead to drug resistance. This
article also aims to show some new methods used to
study drug resistance in 2D and 3D cell cultures, as well
as to understand the role of CSCs as the major contrib-
uting factor in cancer recurrence and later metastasis
development, describing how CSCs can be identified and
isolated.
Review
Drug resistance
Several mechanisms are associated with chemoresistance
of tumor cells, but two of them have been extensively in-
vestigated along the years: apoptosis inhibition [11,19-21]
and multidrug resistance, which is responsible for exporting
cytostatic substances through the cell membrane [22-25].
Multidrug resistance
Various factors can contribute to chemoresistance in tu-
mors, such as the cellular microenvironment and some
molecules synthesized by these cells [23]. The ABC
(ATP-binding cassette) protein superfamily plays an im-
portant role in the distribution of intrinsic and extrinsic
(drugs, for example) molecules to the human organism.
Internalization of these substrates (molecules, drugs) oc-
curs by active transport. Their transport is dependent on
the hydrolysis of ATP. Members of that superfamily
of proteins are expressed in many tissues and their iso-
forms are widely studied. Among them we can mention
the group of MDR proteins [26]. In 1987, researchers
have shown that P-glycoprotein, one of the most import-
ant member of the ABC transporter superfamily, is also
encoded in normal tissues; they used the monoclonal
antibody MRK16 to determine the location of P-gp [27].
Cancer cells show different expression of MDR proteins
and this is a huge contributor to chemoresistance in
tumors [23].
The main form of drug resistance is the capacity of
cells to express genes that encode membrane transport
proteins [22] as P-gp, encoded by ABCB1 (MDR1) gene.
The proteins that form the MDR system are able to alter
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the efflux and influx of many drugs, and so, change the
cytotoxic effects of these drugs [23]. Many chemothera-
peutic drugs, such as anthracyclines, are substrate for
the MDR proteins, and this could impair the effective-
ness of cancer treatment [28-30].
Aran et al. [24] observed that NIH3T3 (fibroblast of
Mus musculus embryo) cells were positively influenced
when treated with colchicine. Higher concentrations of
colchicine increased the expression of the MDR1 gene
that encodes P-glycoprotein, so an augment of the drug
would be directly related to drug resistance.
Januchowski et al. [22] studied six ovarian cancer cell
lines W1MR, W1CR, W1DR, W1VR, W1TR and W1PR
(respectively resistant to methotrexate, cisplatin, doxo-
rubicin, vincristine, topotecan and paclitaxel – that is
the most commonly prescribed drug to the treatment of
ovarian cancer). The W1 cell line was previously estab-
lished by their group years before. It is important to note
that the tissue was obtained from an untreated patient
and the resistant cell lines were obtained by exposure of
the W1 cell line to increasing concentrations of each
drug. Their results showed high levels of P-gp protein
expression in W1PR cell line, pronounced expression in
W1DR and low levels in W1VR, compared to others cell
lines that did not express P-gp, The results suggest that
P-gp is the responsible for chemoresistance in these cell
lines. The authors also found a relation between the
MRP2 transcript level and methotrexate resistance in
the cell lines described above.
Usually, cancer treatment combines surgery and che-
motherapy/radiotherapy in order to improve patient sur-
vival or eradicate the disease. Oosterwijk et al. [31]
concluded that it is possible to sensitize chondrosarcoma
established cell lines and primary cultures to doxorubi-
cin and cisplatin by repairing the apoptotic machinery.
Although there are many drugs that can act on P-gp
to circumvent drug resistance in chemotherapy, their ef-
fective action can be compromised due to the multipli-
city of signal transduction pathways involved in P-gp-
mediated MDR, such as MAPK, JNK, PI3K, among
others; as well as some transcription factors, like NF-κB,
TNF-α, PTEN that could confer different levels of P-gp
expression in different environments and conditions
(reviewed in Sui et al. [32]).
Besides P-gp, another protein that is widely investi-
gated is the MRP1 (multidrug resistance associated
protein 1). This protein is greatly related to chemoresis-
tance in different types of tumors, such as lung cancer, but
its expression is a characteristic of childhood neuroblast-
oma [25].
Increased expression of MRP1 is strongly associated
with the capacity of cancer cells to migrate and form a
secondary tumor [33]. Other studies have shown that
MCF-7 cell line cultured as spheroids exhibited an
increased resistance to doxorubicin and cell-cell interac-
tions could be significant modulators in the drug resistance
inMCF-7 cell line and a resistant variant (MDR-MCF-7)
[34]. These data indicate a link between MDR and tumor
ability of invasiveness and metastasis.
Micro RNAs (miRNA), a family of small noncoding
RNAs that regulate gene expression, can be involved in
chemotherapy resistance through the regulation of MDR
proteins at a post-transcriptional level. The interaction
of miRNAs with the targeted mRNA can negatively
modulate MDR proteins improving the tumor cell res-
ponse to anticancer drugs. miRNAs are heavily explored
because they represent an alternative for combined
therapeutic of cancer. Yang et al. [35] described that
miR-223 can downregulate ABCB1 and mRNA levels,
suggesting that miR-223 plays an important role in the
regulation of MDR proteins mediated by ABCB1 gene
product in HCC cell lines.
The gene ABCC4 encodes the MRP4 protein, which is
found in many tissues like renal tubules and blood cells
and is another efflux membrane transporter. miR-124a
and miR-506 significantly decreased MRP4 protein levels
in HEK293T/17 (normal human embryonic kidney),
however these miRNAs did not change the gene tran-
scription levels [36]. MCF7 mitoxantone-resistant cells
(MCF7/MX) derived from MCF7 cells, overexpress the
breast cancer resistance protein (BCRP), encoded by
the ABCBG2 gene, which is a target of miR-181a. The
induction of miR-181a overexpression increased the
sensitivity of both lines, MCF7 and MCF7/MX, to
mitoxantone [37].
Cell death and chemoresistance
The drug-activated cell death pathway depends on the
cell type. Thus, a chemotherapeutic substance may trig-
ger a large variety of tumor responses according to the
organ or tissue considered. Many of the signals that
elicit apoptosis converge on the mitochondria, which re-
spond to pro-apoptotic signals by releasing cytochrome
c [38]. There are two great classes of chemotherapeutic
drugs: molecules that induce cell death in interphase
cells, frequently by causing DNA damage, like cisplatin
[39,40] (reviewed in Eckstein [41]), and others that in-
duce cell death by mitosis blockage, usually by interfer-
ing in microtubules dynamic, like paclitaxel [42,43].
p53 was the first described tumor suppressor gene as-
sociated with apoptosis and it has been extensively stu-
died along the years, because mutations in this gene
occur in the majority of human tumors. Furthermore,
p53 mutations are frequently associated with advanced
tumor stage and poor patient prognosis. However, p53
mutations alone are not the only responsible for tumor
progression: several upstream and downstream mole-
cules of the p53 pathway (MDM2, p19ARF and Bax) are
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usually altered in human tumors [44]. Nevertheless,
studies have failed to correlate p53 mutations with re-
duced toxicity to anti-cancer agents in some tumors like
melanoma [45].
Mutations can vary according to the tumor tissue, and
different drugs must be tested to attack different types
of cancers. 5-fluorouracil (5-FU), for example, is the
most common antimetabolite used for the treatment of
colorectal cancer. Researchers have demonstrated that
5-FU exerts its cytotoxicity through induction of apop-
tosis, but the drug is not completely effective because of
an inducible chemoresistance mechanism. 5-FU induced
the activation of NF-κB in two colon cancer cell lines
[21] and four of five thymidylate synthase inhibitor-
resistant colon cancer cell lines were found to overex-
press NF-κB [20].
NF-κB is a family of ubiquitous transcription factors
that includes p50/p105, p52/p100, RelA (p65), c-Rel, and
RelB [46]. It is known that numerous proteins, including
C-myc, Cyclin D1, Bcl-2, COX-2, Bcl-xL and Survivin,
are all regulated by NF-κB at the transcriptional level
and linked to chemoresistance. [11,19,47-50] showed
that transfection with adenovirus IκBα super-repressor
strongly inhibited constitutive activation of NF-κB and
significantly enhanced 5-FU and 5-FU/Folinic acid-
mediated growth inhibition.
Many other studies have demonstrated a correlation
between NF-κB and chemoresistance in different cancer
cells. Chemoresistance in pancreatic cancer, for example,
has been associated with activation of NF-κB, and its
inactivation leads to cell sensitization to conventional
therapeutics [51-53]. Gemcitabine remains as the best
treatment available for advanced pancreatic cancer, but
this drug alone activates NF-κB, decreasing the apoptosis
rate in vitro [54,55].
Wang et al. [55] showed that escin, a natural mixture
of triterpene saponins, increased apoptosis rate in BxPC-
3 and PANC-1 cells by downregulating NF-κB, and con-
sequently C-myc, Cyclin D1, Bcl-2, COX-2, Bcl-xL and
Survivin. They also showed that the combination of
gemcitabine and escin was more effective. Xiao & Wei
[56] and Harikumar et al. [57] have already reported that
escin could reduce the activity of NF-κB. Other works
demonstrated that escin exhibited antitumor effects in
various cancer cells [58-61] and enhanced the effects of
paclitaxel and doxorubicin in human hepatocellular car-
cinoma cells.
A long-term treatment of cancer cells with a chemo-
therapeutic drug usually results in cells resistant to the
treatment. Barr et al. [62] established cell lines resistant
to cisplatin with increasing doses of the drug and dem-
onstrated that these cells have increased NF-κB expres-
sion and stem cell-like signature. Treatment of resistant
cells in murine models with genistein, an Akt/NF-κB
inhibitor, sensitizes cells to cisplatin-induced cell death
[63].
Evidences suggest that not only NF-κB, but also PI3K/
Akt signaling pathway, is associated with chemoresis-
tance development in cancers (Figure 1). PI3K-Akt path-
way is a known regulator of cell survival that controls
pro-survival and antiapoptotic proteins such as Cyclin
D1, Bcl-2, Bcl-xL and XIAP [64-67].
Many natural products that activate different stages of
the cell death cascade are synergistic in combination
with effective chemotherapeutic agents. For example,
curcumin, the yellow pigment in Indian saffron, potenti-
ates the antitumor activity of various chemotherapeutic
agents, including paclitaxel, gemcitabine and cisplatin, in
a wide range of cancer cells by suppressing the expres-
sion of important antiapoptotic proteins [68-70].
Natural products have been studied in different tumor
models due to their effective potential against cancer
cells and relatively low cytotoxicity in normal cells
[71-73]. Actually, natural products could protect normal
cells against pathological changes caused by drugs like
doxorubicin [11].
Yang et al. [74] found that tectorigenin, a type of O-
methylated isoflavone, does not induce potent cell death
alone, but significantly sensitizes human ovarian cancer
cells to paclitaxel-induced cytotoxicity by inactivating
the Akt/IKK/IκB/NF-κB signaling pathway. Flavonoids
like tangeretin and genistein showed important chemo-
sensitization of drug-resistant ovarian cancer cells to dif-
ferent agents like cisplatin and taxane drugs, as well as
gemcitabine and topotecan. These natural compounds
increased cell death by downregulating the PI3K/Akt
pathway [75].
PI3K/Akt is another important signaling pathway in-
volved in acquired chemoresistance of many cancers.
Akt is also known as protein kinase B (PKB). All of
its isoforms (Akt1, Akt2 and Akt3) are phosphorylated
(activated) by a phosphatidylinositol 3-kinase (PI3-K) in
response to growth factors to promote cell survival [76].
Increased activation of different isoforms of Akt has
been associated with different cancers [77-79].
A number of works demonstrated that the Akt pathway
is directly related to resistance of cancers against different
drugs like sorafenib, trastuzumab and erlotinib [80-82].
The epigenetic control of Akt and NF-κB is important for
the establishment of drug resistance. Lin et al. [83] found
that RUNX3 suppresses Akt1 transcription by directly
binding to the Akt1 promoter. Zheng et al. [84] showed
that methylation of RUNX3 induces activation of the Akt
signaling pathway. This mechanism of control would be
responsible for inducing docetaxel chemoresistance in
human lung carcinoma and the treatment of docetaxel-
resistant lung cancer cells with a specific DNA methyl-
transferase inhibitor decreased the cell viability.
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Different compounds have been used to target the Akt
pathway. Liu et al. [85] induced apoptosis in gefitinib-
resistant lung cancer cells by using benzyl isothiocyanate,
which suppressed the activity of Akt/MAPK pathways.
Gao et al. [86] found that apigenin, a natural flavonoid,
could be an adjuvant sensitizer in doxorubicin-resistant
hepatocellular carcinoma, once this natural compound
inhibited the PI3K/Akt/Nrf2 pathway in the resistant cells.
Anoikis is a type of programmed cell death that is in-
duced by disruption of cell-matrix interactions in epithe-
lial cells, named so by Frisch and Francis [87], although
there are reports of the anchorage-dependent cell growth
and viability dating back to the 1960’s [88]. This process is
an important step for maintaining the balance between
cell proliferation and cell death in healthy tissues [89]. Ba-
sically, extracellular matrix (ECM) signaling and interac-
tions with epithelial cells determine their correct location,
preventing detached cells to colonize different tissues than
their own. However, an important aspect of chemoresis-
tance in cancer cells (especially in carcinomas) is resist-
ance to anoikis, which can confer these cells the ability to
detach from their original tissue and not only survive but
also migrate to secondary sites and invade other tissues,
i.e. metastasize [90].
Anoikis activation is associated with the inactivation
of pro-survival genes after cytoskeleton rearrangement
[91]. In cancer, pro-survival pathways, such as Akt and
ERK pathways, are activated to suppress anoikis signal-
ing. Researchers have implicated Akt pathway activation
in anoikis suppression during resistance to chemo-
therapeutic agents as mitoxantrone, cisplatin and 5-FU,
but no decreased sensitivity to paclitaxel [92]. In other
study, overexpression of CEACAM6 (Carcinoembryonic
Antigen-related Cell Adhesion Molecule 6) was asso-
ciated with chemoresistance to gemcitabine in pancre-
atic adenocarcinoma [93]. However, Diaz-Monteiro and
McIntyre [94] have found that anoikis resistance is not
directly related to chemotherapy resistance in osteosar-
coma, probably involving distinct activation steps.
Recently, works on miRNAs approached different as-
pects of anoikis resistance and chemoresistance, i.e.,
reducing mobility of anoikis-resistant cells as well as in-
creasing their sensitivity to paclitaxel in endometrial and
ovarian cancer cells [95]. Even though studies have man-
aged to place intermediate proteins in signaling pathways
leading to anoikis resistance, there are many different
pathways that culminate in the evasion of anoikis. Hence,
much is yet to be discovered to elucidate this process in
cancer progression.
Heat shock proteins in tumor resistance
Other sensitizers that have been studied in potential
combinational therapies are the heat shock proteins
(HSPs). HSPs are chaperones with cytoprotective role
into the cells responsible by proper folding of proteins.
HSPs are classified according to their molecular weights
in Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and small
HSPs [96]. Among these proteins, Hsp90, 70, 40 and 27
Figure 1 The role of Akt and NF-κB signaling in drug resistance mechanism of tumor cells. Several drugs induce the activation of Akt and
NF-κB signaling pathways. Akt activation inhibits the P53 and BAD pathways leading to cell survival. Akt also stimulates Ikk, which inhibits IκB and
triggers NF-κB signaling pathway. NF-κB activates C-Myc and COX 2 that are mainly involved in cell proliferation and angiogenesis, respectively.
Both Akt and NF-κB activate the antiapoptotic proteins Bcl-2 and Bcl-xL, inhibiting the Cytochrome-c release from mitochondria, and Cyclin D1,
which contributes to cell cycle progression. Akt and NF-κB also inhibit the caspase cascade by XIAP and Survivin activation, respectively.
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have received special attention in studies that aim to in-
hibit tumor growth and progression. Hsp70 and Hsp90
are proteins directly involved in refolding proteins;
Hsp40 transfers the unfolded protein to Hsp70 by com-
plexing with HIP (Hsp70 interacting protein) and sti-
mulates the ATPase activity of Hsp70; Hsp27 prevents
aggregation of unfolded proteins into the cytoplasm
[97,98].
Jeong et al. [99] demonstrated the association between
Hsp90 inhibition and decrease in proliferation of a non-
small cell lung cancer (NSCLC) cell line resistant to gefi-
tinib. Other study using NSCLC cells showed that treat-
ment with Hsp90 inhibitor ganetespib induced loss of
EML4-ALK gene rearrangement found in this type of
tumor and depletion of multiple oncogenic proteins
[100]. Hsp90 inhibitor CH5164840 showed antitumor
activity on NSCLC cell lines and enhanced the efficacy
of erlotinib. The combination of these compounds sup-
pressed ERK signaling in a cell line resistant to erlotinib
[101]. Hsp90 inhibition lead to apoptosis induction by
mitochondrial pathway in melanoma, cervix, colon, liver
and lung cancer cells and induced apoptosis in cells
overexpressing Bcl-2 [102].
Hsp70 is currently upregulated in several cancer types
and can be induced by drugs that trigger the heatshock
pathway signaling. Hsp70 protects normal and tumor
cells from death by binding to Bax and Apaf-1 after a
stress stimulus [103,104]. A barrier to the complete suc-
cessful of Hsp90 inhibition in treatment of cancers is
that its inhibition increases the Hsp70 expression [105].
Some authors showed that inhibition of Hsp70 alone is
few less or ineffective to cause cell death in tumors,
nevertheless it could enhance the antitumor effects of
other drugs a great coadjuvant in the treatment of can-
cers [106-108]. The Hsp40 group has a role as co-
chaperone for Hsp70 and indirect regulator of Hsp90
and it contains the greatest number of members. In fact,
the diversity of structures and functions of the group
makes targeting Hsp40 very challenging (for review, see
Sterrenberg et al. [109]).
Different works showed the relationship between
Hsp27 and direct activation of Akt, increasing the cell
survival signaling pathway by regulating negatively
pro-apoptotic proteins in different models [110,111].
Kim et al. [112] demonstrated that inactivation of ERK/
p90RSK/HSP27 cascade in SK-OV-3 cells by melatonin
enhances cisplatin-induced apoptosis. Hsp27 inhibition
by quercetin also reduced the viability of A549 cells
when used in combination with cisplatin or gemcitabine
when compared to these drugs alone showing the role of
Hsp27 in chemoresistance [113]. Other studies showed
the antitumor effects of Hsp27 inhibition in combin-
ation with other drugs (for review, see McConnell &
McAlpine [114].
Monolayer x 3D cell culture
Cell culture in a monolayer system, also known as two-
dimensional culture (2D), does not maintain the same
features found in vivo. The development of other culture
systems are growing up to achieve one that better
mimics the in vivo cellular features, very important to
improve studies about cancer disease, for example, in
the evaluation of drug effects in cancer cells [115]. The
three-dimensional culture (3D) is a type of culture that
increases cell interactions with other cells and with the
ECM, which is closer to in vivo conditions [116,117].
The increased cell-cell or cell-matrix interactions ob-
served in 3D culture can: a) augment cell differentiation
[118-120]; b) change cell signaling in response to ECM
compounds [121]; c) modify the gene expression pattern
[122,123]; and d) alter the expression of proteins linked
to cell adhesion to matrix (integrins) and cell-cell ad-
hesion (cadherins) [124]. The expression of integrin and
E-cadherin distribution in spheroids were similar to
in vivo results [125,126].
There are several models of cell culture in a 3D envir-
onment, such as: multicellular spheroids [127,128], mi-
crocarrier beads, synthetic (synthetic gels) or natural
materials (matrigel, a gel with ECM obtained from
mouse sarcoma cells in culture, and type I collagen) that
provide cell growth in a three-dimensional system and
organotypic explant culture [121].
The 3D culture may be a good model for both basic
and applied research. Cancer cells culture in a 3D sys-
tem is very interesting to study cancer disease, for ex-
ample, evaluating the effects of drugs in these cells. Cells
maintained in a 3D environment are organized in mul-
tiple layers that confer a biological barrier to drug diffu-
sion, like small avascular tumor aggregates observed
in vivo [121]. Fourré et al. [129] cultivated fibrosarcoma
cells HT-1080 in a 3D culture type with type I collagen
and showed that doxorubicin cell penetration took about
1 more hour compared to cells grown in a 2D system.
Other works showed similar results with the same drug:
Yip & Cho [130] found that cells cultured in the pres-
ence of collagen hydrogel had higher cell viability and
Millerot-Serrurot et al. [131] observed that ECM pro-
tected cancer cells from anti-migratory effect of doxo-
rubicin. However, in these cases, the decreased drug
penetration was due to mechanical resistance and not
cell chemoresistance [132].
Some cell types become more resistant to cell death
via apoptosis while they are in contact with other cells
or with the ECM, as it occurs in 3D cell cultures. For ex-
ample, cell adhesion mediated by integrins leads to in-
creased expression of integrin receptors and fibronectin,
such as VLA-4, which seems to be related to apoptosis
resistance [133,134]. Also, in some 3D models in which
cells became polarized after the contact with an ECM
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similar to the basement membrane, the expression of
beta4 integrin was associated with resistance to apop-
tosis [135]. This type of resistance, also known as CAM-
DR (cell adhesion mediated drug resistance), is seen today
as a target to anti-cancer therapies [136,137].
Studies have shown that cells are more resistant to
drugs when grown in 3D cultures than when they are in
monolayer. Longati and co-workers [138] tested the re-
sistance of pancreatic ductal adenocarcinoma cell line
(PDAC) in 2D and 3D cultures. The cells are more re-
sistant to gentamicin, CD5, CB7, CB13, Act16412 and
GANT61 when they are in 3D cultures. Human ovary
cancer cells (SKOV3 cells), when cultured in 3D to
mimic ascites, form cell aggregates resistant to paclitaxel
[139,140]. This resistance could be due to high ex-
pression levels of KLK4 (high tumor kallikrein-related
peptidase 4) [140]. Similarly, stem cells isolated from
SKVO3 cultures, when cultivated in a 3D environment
with basement membrane extract scaffold, are resistant
to docetaxol, cisplatin, carboplatin and 5FU. In cells
grown in this model of 3D culture, the expression of
ABCB1 and ABCG2 are increased and could be related
to resistance to the drugs tested [141]. Lung cancer
cells also become resistant to bortezomib when in 3D
cultures [142], as well as MCF-7 cells which become
resistant to 5-FU in specific stages of spheroid formation
[143].
Some genes related to drug resistance in 2D cultures
are over expressed in 3D cultures and could be involved
with drug resistance in these models. Among these
genes, we can mention BCL-2 family members, ABCG2
and ABCB1, CP78 and KLK4. Other interesting hypoth-
esis for drug resistance in 3D cultures is related to the
increased cell adhesion and matrix elements synthesis in
these models, making it difficult for drugs to penetrate
in the spheroids and reach all the cells [138]. However,
some studies show that certain drugs such as doxorubi-
cin can penetrate in spheroids and be incorporated in
cells nuclei within these large structures. In this case the
drug retention does not depend on MDR1 bombs, but
the resistance seems to be related to the expression of
Bcl-2 family members [31].
Fourré and co-workers [129] also show in collagen
rich models that doxorubicin and anthracyclins take
more time to be detected in cell nuclei and that in these
cases it takes longer treatments to reach similar cellular
responses to those seen in 2D cultures.
Nirmalanandhan and co-workers [144] tested 10 dif-
ferent drugs in lung cancer (A549) and bronchioalveolar
cancer (H358) cells cultured in 2D and 3D models with
type I collagen. When tested in H358 cells, 8 of the 10
drugs needed different concentrations to reach the same
effects in 2D and 3D. In A549 cells 7 of the 10 drugs
showed similar effects but in different concentration.
The results depend on the cell line and on the drug
class, and show that more studies should be done to
determine if the mechanisms of chemoresistance in 3D
models share the same features of the mechanisms
observed in 2D cultures. Moreover, it is important to
evaluate if the cell responses to drugs in 3D are more
similar to what happens in vivo than those observed in
2D cultures, making it a new way to test drugs and to
evaluate chemoresistance. A summary of studies with
drug resistance in 2D and 3D cell cultures is presented
in Table 1.
Cancer stem cells
The concept of cancer stem cell (CSC) was stated based
on the organization of multicellular organisms present-
ing somatic stem cell populations that give rise to com-
mitted progenitors which are able to differentiate into
mature cells. Normal cellular hierarchy comprises stem
cells that progressively generate more restricted progeni-
tor cells, yielding all the mature cell types that constitute
a particular tissue. Cancer would simulate organ devel-
opment, exhibiting a similar hierarchy with different cell
populations, including the CSCs, associated to high drug
resistance.
In the strict sense, CSCs and tumor initiating cells
(TICs), i.e., cells that acquired the tumor promoting
mutations are conceptually different. CSCs (and not
other tumor cells) would be the only cells capable of
sustaining tumorigenesis due to their self-renewal and
asymmetric division abilities. TICs are defined as cells
capable of initiating a tumor in immunocompromised
mice [145]. However, the terms CSCs and TICs have
being indistinctly used to refer to the small cellular sub-
population (0.01-1% of total tumor cells) first described
in leukemia and then in breast cancer and others solid
tumors [16,17,146,147]. These cells are able to induce
cancer when transplanted to immunodeficient mice,
have drug resistance and self-renewal ability. It is be-
lieved that the resistance of CSCs to currently used che-
motherapeutics is a major contributing factor in cancer
recurrence and later metastasis development.
According to their phenotypes, CSCs can be identified
and isolated by means of 4 main methodologies: a) cell
sorting by flow cytometry using specific cell surface
markers [148,149]; b) assessment of aldehyde dehydro-
genase (ALDH) activity [150]; c) cell sorting of side-
population (SP) phenotype by Hoechst 33342 exclusion
[151]; d) spheres isolation, since CSCs are able to form
floating colonies from a single cell more efficiently than
their progeny [152] and to grow as spheres in non-
adherent culture conditions [153].
The most commonly used surface markers are CD44+
and CD133+ [17,146]. CSC phenotype in leukemia was
associated with CD44+/CD38- cells [16]. CD44 is a
Niero et al. Journal of Experimental & Clinical Cancer Research 2014, 33:37 Page 7 of 14
http://www.jeccr.com/content/33/1/37
transmembrane glycoprotein believed to be activated in
a wide range of tumors in which it plays a critical role in
cancer cell adhesion, migration, invasion and survival
[154]. It is a multifunctional cell surface adhesion mo-
lecule associated with cell-cell and cell-matrix inter-
action. CD44+ has identified cells with the ability of
give rise to new tumors in vivo, in different types of
cancer. Patient samples of head and neck squamous cell
carcinoma (HNSCC), for example, contain a heteroge-
neous population of cancer cells and the small subpopu-
lation CD44+ contained most of the CSCs, evidenced
by its tumorigenic potential in immunodeficient mice
[155].
CD133 (prominin-1 or AC133) was originally des-
cribed in human hematopoietic stem cells and has sub-
sequently been used as a marker to isolate CSCs from
many tumor types. It is a member of the pentaspan
transmembrane glycoprotein family involved in a variety
of cellular activities. CD133 is found to be selectively
localized in microvilli and other plasma membrane
protrusions irrespectively of cell type and interact with
membrane cholesterol. Wnt, Notch, TGFβ1, Line-1 and
methylation regulate its expression. CD133 is involved
in energy metabolism and in autophagy, which are bene-
ficial for the survival of cancer stem cells.
ALDH activity is an important functional marker of
normal and malignant stem/progenitor cells. ALDHs
contribute to drug resistance through detoxification of
many cytotoxic agents provided that aldehydes are genera-
ted by several metabolic processes (reviewed by Marchitti
et al. [156]). Increased ALDH activity in hematopoietic
stem cells, for example, contributes to metabolize and
detoxify cyclophosphamide [157]. The ALDH family of
enzymes comprises 19 isoforms that can be found in
different cell compartments: nucleus, cytoplasm or mito-
chondria. In a retrospective analysis of breast cancer pa-
tient samples, ALDH1A1, but not ALDH3A1, expression
was found to be predictive of tumor responsiveness to
cyclophosphamide and other oxazaphosphorines treat-
ment [158]. In support of this potential role for ALDH in
CSC resistance to chemotherapeutics, CSC enrichment
was observed in colorectal cancer xenograft tumors after
Table 1 Effects of some drugs and cancer cell mechanisms of drug resistance in monolayer and in three-dimensional
cell cultures
Drug Cell type Effects in 2D and 3D cultures Processes related to chemoresistance Reference
Doxorubicin/
Paclitaxel/
Tamoxifen/
MCF-7 (breast carcinoma) Antiproliferative effect increased in
2D; cells more resistant to drugs in
3D.
Increased ECM production in 3D models,
difficulting drug diffusion.
Horning
et al. [143]
AG1478 SW-480, HT-29, DLD-1, LOVO,
CACO-2. COLO-205, COLO-
206F (Colorectal Cancer Cell
Lines)
Cell viability decreased in a dose-
dependent way in 2D and 3D, but
more clearly in 2D.
Cells in 3D showed decreased expression of
EGFR. ECM signaling can be involved too.
Luca et al.
[98]
5FU/ Docetaxel/
Cisplatin/
Carboplatin
SKOV-3 cell line (epithelial
ovarian cancer). Stem cells
were selected from these
cultures.
Antiproliferative effect increased in
2D. Cells in 3D models more
resistant to drugs.
Decreased apoptotic induction in 3D.
Increased expression of ABCG2 e ABCB1 in 3D.
Chen et al.
[116]
Paclitaxel SKOV-3 (epithelial ovarian
cancer)
Increased expression of KLK4 favors
multicellular aggregates formation
and these are more resistant to
drug.
Increased expression of KLK4. Dong et al.
[115]
Doxorubicin/
Cisplatin
SW1353, CH2879, JJ012,
OUMS27 (chondrosarcoma
cell lines)
In 3D models doxorubicin can
reach cell’s nuclei but cells are
more resistant to the drug.
Drug penetration is not dependent on MDR
activity. Bcl-2 members are important to
resistance.
Van
Oosterwijk
et al. [29]
Taxol/Cisplatin HEY, A2780, SKOV3, OVAC429
(human ovarian cancer)
Cells cultured in 3D are more
resistant to taxol treatment.
Cells from some cell lines did not arrested in
G2-M after taxol treatment.
Frankel
et al. [144]
Doxorubicin HepG2 (human hepatocellular
liver carcinoma) and 3T3-J2
(fibroblasts murine stromal
cells)
Increased cell viability in 3D. 3D
heterospheroids are more resistant
than 2D and homospheroid
models.
Stromal fibroblasts and collagen hydrogel
culture system provides more resistance.
Yip & Cho
[105]
Doxorubicin HT1080 (human fibrosarcoma) In 2D doxorubicin decreased cell
migration, and in 3D the drug did
not affeted cell migration.
EMC proteins in a 3D configuration are able to
protect cancer cells from the antimigratory
effect of doxorrubicin. Environment-mediated
drug resistance.
Millerot-
Serrurot
[106]
Docetaxel/
Cisplatin/5-FU/
Gemcitabine/
Camptothecin
H460, A549, H1650 (lung
cancer)
All drugs showed increased IC-50 in
3D.
Caspase-3 is decreased in 3D. Drugs could not
penetrated into cells in 3D and apoptosis was
decreased.
Godugu
et al. [107]
The table shows authors that compared effects in 2D and 3D cell cultures in the same article.
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cyclophosphamide treatment, and this was correlated with
enhanced ALDH1A1 expression and enzymatic activity.
Antibodies against the ALDH enzyme family are avail-
able, but the vast majority of studies have used cell-
sorting techniques to enrich for cells expressing these
enzymes. Live cells expressing high ALDH activity are
usually identified by the Aldefluor assay and sorted by
fluorescence-activated cell sorting. This approach was
used by Cheung et al. [159] in one of the first studies
isolating ALDH+ cells from acute myeloid leukemia.
ADLH+ enriched cell population was similarly isolated
from breast cancer [160]. In both studies, the isolated
cells presented self-renewal ability and high tumorigenic
potential. ADLH+ cells with CSC phenotype were iso-
lated from several hematopoietic and solid tumors in-
cluding lung, liver, bone, colon, pancreatic, ovarian, head
and neck, and prostate cancers.
The aldefluor activity specific for the CSCs of these
cancers has been attributed to ALDH1A1 and so prog-
nostic studies have been targeted to this isoform. How-
ever, Marcato et al. [161] claim that ALDH1A3 and
other ALDH isoforms activities contribute to aldefluor
positivity.
Additionally, ALDHs participate in ester hydrolysis
and act as antioxidant. Enzymatic aldehyde dehydrogen-
ase activity of some specific isoforms is important for
the preservation of undifferentiated stem cells, by inter-
fering with the biosynthesis of endogenous retinoic acid
(RA) through the oxidation of all-trans-retinal and 9-cis-
retinal. The cytosolic isoform ALDH1A1, associated with
metabolism and detoxification of cyclophosphamide,
plays a role in the differentiation of several cell types
through the oxidation of retinal to RA [156].
RA modulates biological processes like cell prolifera-
tion, differentiation, cell cycle arrest and apoptosis. All-
trans-RA is used to treat acute promyelocytic leukemia,
since it induces differentiation of immature leukemia
blasts into terminally differentiated granulocytes, leading
to a clinical remission in approximately 90% of patients.
Based on these results, retinoic acid effects are being
studied in other cancers and cancer cell lines. The com-
bined use of RA (0.1 μM) and cAMP (1 mM), an im-
portant second messenger, improves the responsiveness
of hepatocarcinoma cell line (HTC) to RA treatment.
RA and cAMP were effective in inhibiting the proli-
feration of HTC cells independently of combined use.
However, treatment with RA and cAMP increased E-
cadherin, Cx26, Cx32 and Ser9-GSK-3β (inactive form)
expression while the expression of Cx43, Tyr216-GSK-
3β (active form) and phosphorylated ERK decreased,
showing that the combined use of RA and cAMP is
more effective in inducing differentiation [162].
The use of the vital dye Hoechst 33342 exclusion as a
method to isolate normal hematopoietic stem cells was
proposed by Goodell et al. [163]. The method defines
an easily identifiable and highly reproducible small cell
population (0.1% of bone marrow cells), presenting
stem cell phenotype. The Hoechst-exclusion SP assay
has the advantage of measuring a functional parameter
of the cells. Widely used in hematological malignancies,
the methodological approach requires additional steps
such as enzymatic cell disaggregation for solid tumor
samples analyses [164]. Both normal and cancer stem
cells express the ABC transporters. The ABC domain of
these transmembrane proteins allows ATP binding and
hydrolysis, and the ABC protein can function as recep-
tor, channel and multidrug transporter, participating in
the efflux of small molecules. These pumps detoxify cells
through the efflux of cytotoxic agents, being responsible
for the exclusion of the dye Hoechst 33342.
SP cells were isolated and characterized in most hu-
man cancers including HNSCC, bladder, ovarian, pan-
creas, lung, hepatocellular carcinomas, osteosarcoma and
Ewing’s (for review, see Tirino et al. [164]). SP cells were
consistently shown to represent a stem cell-enriched
population. Compared to non-SP cells, a smaller number
of SP cells are able to grow as tumors when injected in
immunodeficient (NOD/SCID) mice.
Breast cancer cell lines, like MDA-MB-231 and MCF-7,
show anoikis-resistance in drug treatments with doxorubi-
cin. The SP cells fraction in the anoikis-resistant cancer
cells seems to be higher than the parental cells [165].
There are reported mechanisms that contribute to SP
chemoresistance including relative quiescence, expression
of ABC transporters and/or MDR1, a more efficient
DNA-repair capability, and the elevated expression of
anti-apoptotic proteins.
The high tumorigenic efficiency of SP cells is associ-
ated with drug resistance and with the presence of other
CSC markers, such as ALDH+, CD133+ or CD44+. He
et al. (2013) proposed the phenotypical modulation of
CSCs, which involves the conversion of SP to non-SP cells
(and vice versa), to be under PI3k/AKT and β-catenin
/CBP signaling pathway. Beta-catenin accumulation en-
hanced the transition from non-SP to SP phenotype, and
siRNA against any of the downstream signals abrogated
the conversion of non-SP to SP cells in breast and bladder
cancer cell lines.
Other method for CSC isolation was based on the ob-
servations of Reynolds et al. [166] that some cells of the
central nervous system were able to grow in suspension
when plated on non-adherent surface, forming struc-
tures named spheres or neurospheres. These floating
colonies were able to self-renewal, once when enzymati-
cally dissociated, they originated several new spheres.
Their stem cell phenotype was confirmed by the ability
to originate different cell types under adequate stimula-
tion (astrocytes, neuron or oligodendrocytes). The floating
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sphere formation is consequence of the ability to grow in-
dependently of surface anchorage and resistance to anoikis
associated with high clonogenicity, features shared by both
normal and cancer stem cells.
Spheres were grown from different human cancer
samples and cancer cell cultures and they consisted
mainly of CSCs (review in Alamgeeret al. [167]). SCLC
and NSCLCCD133+ cells, when submitted to long-term
culture as spheres, could modify their phenotype to
CD133- cells [153]. The phenotype modulation of CSCs
is important to define more efficient therapies. MCF-7
cell line long-term spheroids showed high degree of cell
differentiation, organizing duct-like structures [119].
The CSC model represents a very important tool in
cancer biology, especially in relation to the problem of
drug resistance. CSC/TIC cells may exist independently
of the described markers and the cellular plasticity may
be much more relevant. Nevertheless, the current identi-
fication of markers and pathways is already underpin-
ning some novel developments in therapeutic strategies
for patients with cancer.
Conclusions
The resistance to chemotherapy was described in cancer
longtime ago, being responsible for most of treatment
failures. Remarkable progress has been achieved in un-
derstanding the tumorigenesis and cancer progression
molecular mechanisms, contributing to the elucidation
of some aspects associated with lack of response to
treatment. Traditionally, it has been proposed that
genetic instability would be responsible for generation
of drug resistant tumor cells, according to the clonal
theory of cancer development. Alternatively, cancer cells
present different mechanisms of drug resistance includ-
ing innate mechanisms that operate at stem cells and
functional responses that result in modulation of in-
tracellular signaling pathways. The major contribution
of the study of the drug resistance mechanisms is the
definition and implementation of more effective, and
perhaps personalized, treatment protocols. Multiple sen-
sitization using natural products and combined pro-
tocols are currently in use to reduce or deplete the
resistance; however the establishment of 3D cell cul-
tures, a system closer to the in vivo tumor, would repre-
sent a valuable tool to cancer treatment.
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